Full product catalog is available after authentication authenticate here!
Free US shipping for orders above $200
This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.
| 5mg*10vials | $80.00 | $90.00 |
| 10mg*10vials | $160.00 | $170.00 |
| 15mg*10vials | $220.00 | $230.00 |
| 20mg*10vials | $280.00 | $290.00 |
| 30mg*10vials | $420.00 | $430.00 |
HPLS
Testing
Endotoxin
Assay
TYMC
Test
TYMC
Test
Heavy Metal
Screening
| Molecular Formula | C194H312N54O59S2 |
|---|---|
| Molecular Weight | 4409.01 |
| CAS Number | 1415456-99-3 |
| Appearance | White to off-white Powder |
| Composition | Lyophilized powder – requires reconstitution |
Cagrilintide mimics the action of amylin, a naturally occurring hormone secreted by the pancreas alongside insulin. Amylin plays an important role in regulating appetite and food intake. Cagrilintide’s main mechanisms include:
Slowing gastric emptying – This prolongs the feeling of fullness after meals.
Reducing appetite – Signals to the brain help reduce hunger and cravings.
Decreasing calorie intake – Over time, this can help create a calorie deficit for weight loss.
Significant weight loss when used alone or with semaglutide
Improved metabolic health markers, such as blood sugar control and lipid profile
Once-weekly injection for convenience
Dual action when paired with GLP-1 agonists, potentially offering better results than either drug alone
Research Applications
Cagrilintide is under investigation for its potential in addressing multiple metabolic conditions:
Obesity and Overweight: Clinical trials have demonstrated dose-dependent weight loss, with studies reporting up to 10.8% body weight reduction over 26 weeks at higher doses (e.g., 4.5mg). Its ability to suppress appetite and reduce food intake makes it a valuable tool for obesity research.
Type 2 Diabetes: Cagrilintide is being studied for its effects on blood sugar control, particularly in combination with GLP-1 agonists like semaglutide (CagriSema), showing improved HbA1c levels and weight loss in phase 2 and 3 trials.
Metabolic Health: Preclinical studies indicate benefits in glucose and lipid metabolism, supporting research into insulin resistance and related conditions.
Combination Therapies: Cagrilintide’s synergistic effects with GLP-1 agonists (e.g., semaglutide) and dual GLP-1/GIP agonists (e.g., tirzepatide) are being explored for enhanced weight loss and glycemic control.
Commonly reported side effects are similar to those of other gut hormone-based therapies:
These effects are usually mild to moderate and may improve as the body adapts.
All product is sold solely for scientific research purposes. Researchers are responsible for ensuring compliance with local regulations and institutional guidelines. Keep out of reach of children and unauthorized personnel.
1688pharmacy is more than just a trusted supplier of research peptides. We are committed to scientific advancement, dedicated to providing the highest quality pharmaceutical-grade compounds that empower researchers and clients to achieve their goals.
Our proprietary processes and meticulous sourcing of premium materials ensure that every peptide we offer meets the most stringent pharmaceutical standards with verified 99% purity.
Every peptide undergoes rigorous third-party laboratory testing using advanced techniques like HPLC, LC-MS, and NMR. Complete Certificates of Analysis available for transparency and verification.
We provide expedited worldwide shipping with reliable tracking and discreet packaging. Our dedicated customer support team assists with orders, storage guidelines, and product inquiries promptly.